Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)
Carbapenem-Resistant Enterobacteriaceae Infection, Fecal Microbiota Transplantation
About this trial
This is an interventional treatment trial for Carbapenem-Resistant Enterobacteriaceae Infection focused on measuring FMT, CRE
Eligibility Criteria
Inclusion Criteria: All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong Rectal swabs or stool specimens showing the presence of CRE Positive CRE specimen within one week of commencement Exclusion Criteria: Pregnancy Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy) Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L) Recent antibiotic use within 30 days prior to consent Contraindications for retention enema (intestinal obstruction, ileus and gut perforation).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Fecal microbiota transplant
Sham fecal microbiota transplant
This group's subject will receive an infusion of 125mL fecal suspension via enema.
This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.